Disclosures experts

All participating experts have declared that the presentions provide a balanced view of therapeutic options and are entirely free of promotional bias.

Other potential relevant (financial) relationships or activities are disclosed below.
(Date of disclosures: april 2022)

Fredrik Schjesvold, MD, PhD

Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway

Disclosure

Board membership:AbbVie, Amgen, Celgene, Janssen, Novartis, and Oncopeptides AB
Research Grants: Celgene, GlaxoSmithKline, Janssen, Oncopeptides AB, and Sanofi
Shareholder: Nordic Nanovector, Oncopeptides
Honorarium:Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, Oncopeptides AB, Schain, Skylite DX, Sanofi, and Takeda

Professor Xavier Leleu, MD, PhD

Department of Hematology, Academic Hospital of Poitiers, France

Disclosure

Consultancy: Janssen-Cilag, Celgene-Bristol Myers Squibb, Amgen, Takeda, Novartis, Merck, Gilead Sciences, Abbvie, Roche, Karyopharm Therapeutics, Oncopeptides, Carsgen Therapeutics, and GlaxoSmithKline
Honorarium: Janssen-Cilag, Celgene-Bristol Myers Squibb, Amgen, Novartis, Takeda, Sanofi, Abbvie, Merck, Roche, Karyopharm Therapeutics, Carsgen Therapeutics, Oncopeptides, and GlaxoSmithKline
Travel/accommodations/meeting expenses unrelated to activities listed: Takeda

Agoston Gyula Szabo, MD

Department of Hematology, Rigshospitalet Copenhagen, Denmark

Disclosure

Consultancy: Takeda, Sanofi, Janssen
Honorarium: Sanofi

Inger Nijhof, MD, PhD

Department of Internal Medicine, St. Antonius Hospital, The Netherlands

Disclosure

Board membership: Amgen, Janssen, Celgene-Bristol Myers Squibb
Honorarium: Amgen, Janssen, Celgene-Bristol Myers Squibb, Sanofi

Ville Varmavuo, MD PhD

Chief Medical Officer in Education, Internal Medicine, Kotka, Finland

Disclosure

Consultancy: Abbvie, Amgen, Celgene, Janssen-Cilag, Roche, Sanofi
Honorarium: Sanofi

Valdas Peceliunas, MD

Department of Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

Disclosure

Honorarium: Sanofi
Clinical trials, principal investigator: Sanofi

Isabelle Vande Broek, MD, PhD

Department of Internal Medicine, St. Antonius Hospital, The Netherlands

Disclosure

Honorarium: Sanofi

Disclaimer: The purpose of this e-learning is to provide you as an HCP with relevant information on the basis of which you can draw your own conclusions. This information is not intended to provide recommendations regarding indications, dosages, or other statements not listed in the Summary of Product Characteristics of the products concerned or not listed in the local applicable guidelines for multiple myeloma.